Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 11:19 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1849–1872 of 3,759 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Phase duration Clear all

Conditions: Pancreatic Cancer
Interventions: protein analysis, laboratory biomarker analysis; Genetic · Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: Not listed
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 3
States / cities: Nashville, Tennessee

Conditions: End Stage Renal Disease
Interventions: Dialysis session of at least 4.25 hours; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 7,053 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 2
States / cities: Waltham, Massachusetts • Minneapolis, Minnesota

Conditions: Irritable Bowel Syndrome With Constipation
Interventions: Linaclotide or Matching Placebo; Drug
Lead sponsor: Ironwood Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 805 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 107
States / cities: Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 97 more

Conditions: Brain Cancer, Brain Stem Glioma
Interventions: Radioactive iodine-labeled monoclonal antibody omburtamab, External Beam Radiotherapy; Drug · Radiation
Lead sponsor: Y-mAbs Therapeutics; Industry
Eligibility: 2 Years to 21 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 2
States / cities: New York, New York

Conditions: Recurrent Low Grade Astrocytoma, Recurrent WHO Grade 2 Glioma, Refractory Low Grade Astrocytoma, Refractory Low Grade Glioma, Refractory WHO Grade 1 Glioma
Interventions: Biospecimen Collection, Magnetic Resonance Imaging, Quality-of-Life Assessment, Questionnaire Administration, Selumetinib Sulfate, Vinblastine Sulfate; Procedure · Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 2 Years to 25 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 91
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Loma Linda, California + 77 more

Conditions: Metastatic Breast Cancer
Interventions: PF-05280014, Paclitaxel, Herceptin®; Biological · Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 707 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 4
States / cities: Plainville, Connecticut • Southington, Connecticut • Boca Raton, Florida + 1 more

Conditions: Epilepsy
Interventions: Levetiracetam; Drug
Lead sponsor: Drexel University College of Medicine; Other
Eligibility: 60 Years to 90 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Non-Small-Cell Lung Cancer
Interventions: Amivantamab, Lazertinib, Carboplatin, Pemetrexed; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 751 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 17
States / cities: Duarte, California • La Jolla, California • Orange, California + 14 more

Conditions: Gulf War Syndrome
Interventions: Curcumin, Glutathione, Placebo; Drug · Other
Lead sponsor: South Florida Veterans Affairs Foundation for Research and Education; Federal
Eligibility: 35 Years to 70 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Neuroendocrine Tumors
Interventions: 177Lu-edotreotide PRRT, Everolimus, Amino-Acid Solution; Drug · Other
Lead sponsor: ITM Solucin GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2029
U.S. locations: 6
States / cities: Gilbert, Arizona • Stanford, California • Tampa, Florida + 3 more

Conditions: Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
Interventions: rHSC-DIPGVax, Balstilimab, Zalifrelimab; Biological · Drug
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: 12 Months to 18 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 3
States / cities: Orange, California • Chicago, Illinois • Boston, Massachusetts

Conditions: Benign Prostatic Hyperplasia (BPH), Enlarged Prostate
Interventions: 2.5 mg NX-1207, 0.125 mg NX-1207, finasteride; Drug
Lead sponsor: Nymox Corporation; Industry
Eligibility: 45 Years to 75 Years · Male only
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 30
States / cities: Huntsville, Alabama • Tucson, Arizona • Little Rock, Arkansas + 27 more

Conditions: Blood Loss, Surgical, Blood Loss, Postoperative, Uterine Atony
Interventions: Calcium Gluconate, Saline; Drug · Other
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older · Female only
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Lung Large Cell Carcinoma, Lung Squamous Cell Carcinoma, Minimally Invasive Lung Adenocarcinoma, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7
Interventions: Bevacizumab, Cisplatin, Docetaxel, Etoposide, Filgrastim, Pegfilgrastim, Radiation Therapy; Biological · Drug · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2027
U.S. locations: 61
States / cities: Mobile, Alabama • Jonesboro, Arkansas • Little Rock, Arkansas + 51 more

Conditions: Carcinoma, Hepatocellular
Interventions: RO7070179; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 7
States / cities: Indianapolis, Indiana • New York, New York • Canton, Ohio + 1 more

Conditions: Dementia, Cognitive Dysfunction
Interventions: Preventing Loss of Independence through Exercise (PLIE); Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 288 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Breast Cancer
Interventions: Radiation Therapy, Capecitabine; Radiation · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Disorder Related to Lung Transplantation, Chronic Lung Allograft Dysfunction
Interventions: Pirfenidone Capsule, Placebo Capsule; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Oral Cavity Squamous Cell Carcinoma
Interventions: NisinZ® P, Surgery (non-interventional, standard of care); Drug · Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Healthy
Interventions: TD-0714, Placebo Comparator; Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Chronic Myeloid Leukemia, Chronic Phase, Adult CML, Leukemia, Myeloid, Leukemia,Myeloid, Chronic
Interventions: Single Agent Asciminib, Low TKI, Elective Free Treatment; Drug · Combination Product · Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 8
States / cities: Birmingham, Alabama • Atlanta, Georgia • Augusta, Georgia + 5 more

Conditions: Chronic Hepatitis C Virus
Interventions: VX-222, telaprevir, ribavirin, peginterferon-alfa-2a; Drug · Biological
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 28
States / cities: Birmingham, Alabama • San Diego, California • Englewood, Colorado + 25 more

Conditions: Acute GVHD
Interventions: Sirolimus, Prednisone; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: Not listed
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 21
States / cities: Duarte, California • Los Angeles, California • Gainesville, Florida + 16 more

Conditions: Central Nervous System Neoplasms, Head and Neck Neoplasms
Interventions: EPO906 (epothilone B); Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

Studying Biomarkers in Patients With Pancreatic Cancer

A Cluster-randomized, Pragmatic Trial of Hemodialysis Session Duration

Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Convection-Enhanced Delivery of 124I-Omburtamab for Patients With Non-Progressive Diffuse Pontine Gliomas Previously Treated With External Beam Radiation Therapy

A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma

A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02)

Levetiracetam: The Anti-Convulsant of Choice for Elderly Patients With Dementia

Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer

Glutathione vs. Curcumin Clinical Trial

Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients

rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG

Phase 2 Study of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) (Enlarged Prostate)

Prophylactic Intravenous Calcium Gluconate to Decrease Blood Loss at Time of Cesarean Delivery in Pregnant Patients at High Risk for Uterine Atony

Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult Participants With Hepatocellular Carcinoma (HCC)

Preventing Loss of Independence Through Exercise in Community Living Centers

Xeloda (Capecitabine) and External Beam Radiation

Studying the Treatment Effect of Pirfenidone in Chronic Lung Allograft Dysfunction (STOP-CLAD)

Nisin in Oral Cavity Squamous Cell Carcinoma (OCSCC)

Single Ascending Dose Study of TD-0714 in Healthy Subjects

Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase

A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis

A Study to Evaluate Steroid-free Treatment for Standard-Risk aGVHD (BMT CTN 1501)

EPO906 Plus Radiation Therapy for the Treatment of Cancer Patients